Prioritization in inflammatory bowel disease therapy

References

• Herrlinger KR, Stange EF. 25 years of biologicals in IBD: what’s all the hype about? J Internal Medicine. doi: 10.1111/joim.13345
   Web of Science ®Google Scholar
• Sturm A, Atreya R, Bettenworth D, et al. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004. Z Gastroenterol. 2022;60(3):332–4182. doi: 10.1055/a-1713-3941
   PubMedGoogle Scholar
• Kucharzik T, Dignass AU, Atreya R, et al. Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline. Z Gastroenterol. 2020;58(12):e241–e326. doi: 10.1055/a-1296-3444
   PubMedGoogle Scholar
• Singh S, Proctor D, Scott FI, et al. AGA technical review on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease gastroenterology. Gastroenterology. 2021;160(7):2512–2556. doi: 10.1053/j.gastro.2021.04.023
   PubMed Web of Science ®Google Scholar
• Singh S, Allegretti JR, Siddique SM, et al. AGA technical review on the management of moderate to severe ulcerative colitis. Gastroen-Terology. 2020;158(5):1465–1496. doi: 10.1053/j.gastro.2020.01.007
   PubMed Web of Science ®Google Scholar
• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohn’s & Colitis. 2020;14:4–22. DOI:10.1093/ecco-jcc/jjz180
   PubMed Web of Science ®Google Scholar
• Raine T, Bonovas S, Burisch J, et al. J Crohns Colitis. ECCO guidelines on therapeutics in ulcerative colitis: Medical treatment. J Crohns Colitis. 2022;16(1):2–17. doi: 10.1093/ecco-jcc/jjab178
   PubMed Web of Science ®Google Scholar
• Raine T, Verstockt B, Kopylov U, et al. ECCO topical review: Refractory IBD. J Crohns Colitis. 2021;15(10):1605–1620. doi: 10.1093/ecco-jcc/jjab112
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Panes J, Sandborn WJ, et al. Defining disease severity in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14(3):348–354. doi: 10.1016/j.cgh.2015.06.001
   PubMed Web of Science ®Google Scholar
• Stallmach A, Bokemeyer B, Helwig U, et al. Predictive parameters for the clinical course of Crohn’s disease: development of a simple and reliable risk model. Int J Colorectal Dis. 2019;34(10):1653–1660. doi: 10.1007/s00384-019-03369-0
   PubMed Web of Science ®Google Scholar
• Schmidt C, Bokemeyer B, Lügering A, et al. Clinical predictors for a complicated course of disease in an inception cohort of patients with ulcerative colitis: results from the prospective, observational EPICOL study. Int J Colorectal Dis. 2022;37(2):485–493. doi: 10.1007/s00384-022-04098-7
   PubMed Web of Science ®Google Scholar
• Cesarini M, Collins GS, Rönnblom A, et al. Predicting the individual risk of acute severe colitis at diagnosis. J Crohn‘s And Colitis. 2017;11:335–341.
   PubMed Web of Science ®Google Scholar
• Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749–753. doi: 10.1136/gut.2005.082909
   PubMed Web of Science ®Google Scholar
• Dulai PS, Singh S, van de Casteele NV, et al. Should we divide Crohn’s disease into ileum-dominant and isolated colonic diseases? Clin Gastroenterol Hepatol. 2019;17(13):2634–2643. doi: 10.1016/j.cgh.2019.04.040
   PubMed Web of Science ®Google Scholar
• Barberio B, Gracie DJ, Black CJ, et al. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis. Gut 2022. doi : 10.1136/gutjnl-2022-328052. Online ahead of print
   Google Scholar
• Burr NE, Gracie DJ, Black CJ, et al. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut. 2022;71(10):1976–1987. doi: 10.1136/gutjnl-2021-326390
   Web of Science ®Google Scholar
• Moja S, Danese S, Fiorino G, et al. Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn’s disease. Aliment Pharmacol There. 2015;41:1055–1065. doi: 10.1111/apt.13190
   PubMed Web of Science ®Google Scholar
• Loftus EV, Panés J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn´s disease. N Engl J Med. 2023;388(21):1966–1980. doi: 10.1056/NEJMoa2212728
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med. 1997;337:1029–1036. doi: 10.1056/NEJM199710093371502
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti–tumor necrosis factor monoclonal antibody (Adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–333. doi: 10.1053/j.gastro.2005.11.030
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, D´haens G, Targan S, et al. Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology. 1999;117(4):761–769. doi: 10.1016/S0016-5085(99)70332-X
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med [ the CLASSIC-I trial. Gastroenterology 2006;130:323–33]. 2007;146:829–838. doi: 10.7326/0003-4819-146-12-200706190-00159
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357:228–238. doi: 10.1056/NEJMoa067594
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721. DOI:10.1056/NEJMoa1215739
   PubMed Web of Science ®Google Scholar
• Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618–627.e3. doi: 10.1053/j.gastro.2014.05.008
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946–1960. doi: 10.1056/NEJMoa1602773
   PubMed Web of Science ®Google Scholar
• D’Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022 May 28;399(10340):2015–2030. doi: 10.1016/S0140-6736(22)00467-6
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–1395. doi: 10.1056/NEJMoa0904492
   PubMed Web of Science ®Google Scholar
• Singh S, Hassan Murad M, Fumery M, et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis. Lancet. 2021 Dec;6:1002–1014.
   Web of Science ®Google Scholar
• Visuri I, Eriksson C, Olén O, et al. Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register. Aliment Pharmacol Ther. 2021 Oct;54(7):931–943.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Arkkila P, Armuzzi A, et al. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. BMC Gastroenterol. 2022;22(1):291. doi: 10.1186/s12876-022-02347-1
   PubMed Web of Science ®Google Scholar
• Hahn GD, Golovics PA, Wettwittayakhlang P, et al. Is there a best first line biological/small molecule in IBD: Are we ready for Sequencing? Biomedicines. 2022;10(4):749.
   PubMed Web of Science ®Google Scholar
• Sands BE, Irving PM, Hoops T, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomized, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399(June 11):2200–2211. doi: 10.1016/S0140-6736(22)00688-2
   PubMedGoogle Scholar
• Parrot L, Dong C, Carbonnel F, et al. Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn’s disease refractory to anti- tumour necrosis factor. Aliment Pharmacol Ther. 2022;55(4):380–388. doi: 10.1111/apt.16714
   PubMed Web of Science ®Google Scholar
• Schmitt H, Billmeier U, Dieterich W, et al. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease. Gut. 2019 May;68(5):814–828.
   PubMed Web of Science ®Google Scholar
• Wu G, Yang Y, Liu M, et al. Systematic review and network meta-analysis:comparative efficacy and safety of biosimilars, biologics and JAK1 inhibitors for active Crohn disease. Front Pharmacol. 2021;12. doi: 10.3389/fphar.2021.655865
   Web of Science ®Google Scholar
• Rui M, Fei Z, Wang Y, et al. Will the inducing and maintaining remission of non-biological agents and biological agents differ for Crohn’s disease? The evidence from the network meta-analysis. Front Med. 2021 Sep 1;8:679258. doi: 10.3389/fmed.2021.679258
   Web of Science ®Google Scholar
• Zakersky - Banaszak O, Lykowska-Szuber L, Walczak M, et al. Cytotoxicity of thiopurine drugs in patients with inflammatory bowel disease. Toxics. 2022;10(4):151. doi: 10.3390/toxics10040151
   PubMed Web of Science ®Google Scholar
• Akbar A, Orchard Powell N, Powell N, et al. Influence of comorbidities on treatment considerations for first-line biologic prescribing in patients with inflammatory bowel disease in the UK. Frontline Gastroenterol. 2022;13(6):490–496. doi: 10.1136/flgastro-2021-101995
   PubMed Web of Science ®Google Scholar
• Singh S, Facciorusso A, Dulai PS, et al. Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020;18(1):69–81. doi: 10.1016/j.cgh.2019.02.044
   PubMed Web of Science ®Google Scholar
• Kirchgesner J, Lemaitre M, Carrat F, et al. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018;155(2):337–346. doi: 10.1053/j.gastro.2018.04.012
   PubMed Web of Science ®Google Scholar
• Kirchgesner J, Desai RJ, Beaugerie L, et al. Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2022;20(2):314–324. doi: 10.1016/j.cgh.2020.12.030
   PubMed Web of Science ®Google Scholar
• Bohm M, Xu R, Zhang Y, et al. Comparative safety and effectiveness of vedolizumab to tumor necrosis factor antagonist therapy for Crohn’s disease. Aliment Pharmacol Ther. 2020;52(4):669–681. doi: 10.1111/apt.15921
   PubMed Web of Science ®Google Scholar
• Fiske J, Liu E, Limdi JK, et al. Safety and effectiveness of ustekinumab in elderly Crohn’s disease patients. Eur J Gastroenterol Hepatol. 2022;34(11):1132–1139. doi: 10.1097/MEG.0000000000002436
   PubMed Web of Science ®Google Scholar
• Chupin A, Perduca V, Meyer A, et al. Systematic review with meta-analysis: comparative risk of lymphoma with anti- tumor necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52:1289–1297. doi: 10.1111/apt.16050
   PubMed Web of Science ®Google Scholar
• Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318(17):1679–1686. doi: 10.1001/jama.2017.16071
   PubMed Web of Science ®Google Scholar
• Amiot A, Seksik P, Reimund JM, et al. Prevalence of anti-TNF contraindications in Crohn’s disease: A cross-sectional survey from the GETAID. digital Liver Dis. 2022. May 14p. S1590
   Google Scholar
• Shebab M, Alrashed F, Heron V, et al. Comparative efficacy of biologic therapies for inducing response and remission in fistulizing Crohn’s disease: Systematic review and network meta-analysis of randomized controlled trials. Inflamm Bowel Dis. 2022;29(3):367–375. doi: 10.1093/ibd/izac103
   Web of Science ®Google Scholar
• Lee M, Parker CE, Taylor SR, et al. Efficacy of medical therapies for fistulizing Crohn’s disease: Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(12):1879–1892. doi: 10.1016/j.cgh.2018.01.030
   PubMed Web of Science ®Google Scholar
• Gjuladin-Hellon T, Iheozor-Ejiofor Z, et al. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2019; 8, Art. No.: CD010233. doi: 10.1002/14651858.CD010233.pub3
   Web of Science ®Google Scholar
• Beelen EMJ, Nieboer D, Arkenbosch JHC, et al. Risk prediction and comparative efficacy of anti-TNF vs Thiopurines, for preventing postoperative recurrence in Crohn’s disease: A pooled analysis of 6 trials. Clin Gastroenterol Hepatol. 2021;S1542.
   PubMed Web of Science ®Google Scholar
• Yanai H, Kagramanova A, Knyazev O, et al. Endoscopic postoperative recurrence in Crohn’s disease after curative ileocecal resection with early prophylaxis by anti-TNF, vedolizumab or Ustekinumab: A real-world multicenter European study. J Crohn’s Colitis. 2022;doi. doi: 10.1093/ecco-jcc/jjac100
   Google Scholar
• Losurdo G, Iannone A, Contaldo A, et al. Escherichia coli Nissle 1917 in ulcerative colitis treatment: Systematic review and meta-analysis. J Gastrointestin Liver Dis. 2015 Dec;24(4):499–505.
   PubMed Web of Science ®Google Scholar
• Stange EF. Steroid-refractory ulcerative colitis: a critical review of national and international guideline recommendations. Z Gastroenterol. 2021;59(11):1214–1223. doi: 10.1055/a-1482-9273
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476. doi: 10.1056/NEJMoa050516
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780–787. doi: 10.1136/gut.2010.221127
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85–95. doi: 10.1053/j.gastro.2013.05.048
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710. doi: 10.1056/NEJMoa1215734
   PubMed Web of Science ®Google Scholar
• Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201–1214. doi: 10.1056/NEJMoa1900750
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7):616–624. doi: 10.1056/NEJMoa1112168
   PubMed Web of Science ®Google Scholar
• Feagan BG, Danese S, Loftus EV, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (selection): a phase 2B/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397(10292):2372–2384. doi: 10.1016/S0140-6736(21)00666-8
   PubMed Web of Science ®Google Scholar
• Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113–2128. doi: 10.1016/S0140-6736(22)00581-5
   PubMed Web of Science ®Google Scholar
• Panaccione R, Ghosh S, Middleton A, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400. doi: 10.1053/j.gastro.2013.10.052
   PubMed Web of Science ®Google Scholar
• Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab versus Adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381(13):1215–1226. doi: 10.1056/NEJMoa1905725
   PubMed Web of Science ®Google Scholar
• Panes J, Colombel J-F D, Haens GR, et al. Higher vs standard adalimumab induction and maintenance dosing regimens for treatment of ulcerative colitis: SERENE UC trial results. Gastroenterology. 2022;162(7):1891–1910. doi: 10.1053/j.gastro.2022.02.033
   PubMed Web of Science ®Google Scholar
• Meyer A, Fumery M, Peyrin-Biroulet L, et al. Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study. Scand J Gastroenterol. 2022;57(12):1454–1462. doi: 10.1080/00365521.2022.2095668
   PubMed Web of Science ®Google Scholar
• Danese S, Sands BE, Abreu MT, et al. Early symptomatic improvement after ustekinumab therapy in patients with ulcerative colitis: 16-week data from the UNIFI trial. Clin Gastroenterol Hepatol. 2022;20(12):S2858–2867.e5. doi: 10.1016/j.cgh.2022.02.050
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016;374(18):1754–1762. doi: 10.1056/NEJMoa1513248
   PubMed Web of Science ®Google Scholar
• Laharie D, Boureille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380(9857):1909–1915. doi: 10.1016/S0140-6736(12)61084-8
   PubMed Web of Science ®Google Scholar
• Schmidt KJ, Herrlinger KR, Emmrich J, et al. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. Aliment Pharmacol Ther. 2013 Jan;37(1):129–136. doi: 10.1111/apt.12118
   PubMed Web of Science ®Google Scholar
• Schmidt KJ, Müller N, Dignass A, et al. Long-term outcomes in steroid-refractory ulcerative colitis treated with tacrolimus alone or in combination with purine analogues.J Crohns Colitis. 2016 Jan;10(1):31–37. doi: 10.1093/ecco-jcc/jjv175
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Ovesen PD, Brynskov J, et al. Tofacitinib for acute severe colitis: a systematic review. J Crohns Colitis. 2023. doi: 10.1093/ecco-jcc/jjad036
   PubMedGoogle Scholar
• Lasa JS, Olivera PA, Danese S, et al. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet online Nov 29, 2021; doi: 10.1016/S2468-1253(21)00377-0
   Google Scholar
• Singh S, Murad HM, Fumery M, et al. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: An updated network meta-analysis. Clin Gastroenterol Hepatol. 2020;18(10):2179–2191. doi: 10.1016/j.cgh.2020.01.008
   PubMed Web of Science ®Google Scholar
• Straatmijer T, Biemans VBC, Visschedijk M, et al. Superior effectiveness of tofacitinib compared to vedolizumab in anti-TNF experienced ulcerative colitis patients: a nationwide Dutch registry study. Clin Gastroenterol Hepatol. 2022;21:S1542-3565(22)00510–9.
   Web of Science ®Google Scholar
• Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55(1):47–53. doi: 10.1136/gut.2005.068809
   PubMed Web of Science ®Google Scholar
• Pudipeddi A, Ko Y, Paramsothy S, et al. Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. Ther Adv Gastroenterol. 2022;15:1–17.
   Web of Science ®Google Scholar
• Pugliese D, Privitera G, Crispino F, et al. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study. Aliment Pharmacol Ther. 2022;56(1):95–109. doi: 10.1111/apt.16923
   PubMed Web of Science ®Google Scholar
• Cheng D, Kochar B, Cai T, et al. Risk of infections with ustekinumab and tofacitinib compared to tumor necrosis factor α antagonists in inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2022;20(10):S2366–2372.e6. doi: 10.1016/j.cgh.2022.01.013
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Panés J, D’Haens GR, et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials. Clin Gastroenterol Hepatol. 2019;17(8):1541–1550. doi: 10.1016/j.cgh.2018.11.035
   PubMed Web of Science ®Google Scholar
• Kochar BD, Cheng D, Cai T, et al. Comparative risk of thrombotic and cardiovascular events with tofacitinib and anti-TNF agents in patients with inflammatory bowel diseases. Dig Dis Sci. 2022 Nov;67(11):5206–5212.
   PubMed Web of Science ®Google Scholar
• Akiyama S, Rai V, Rubin DT. Pouchitis in inflammatory bowel disease: a review of diagnosis, prognosis, and treatment. Intest Res. 2021;19(1):1–11 28. doi: 10.5217/ir.2020.00047
   PubMed Web of Science ®Google Scholar
• Huguet M, Pereira B, Goutte M, et al. Systematic review with meta-analysis: Anti-TNF rherapy in refractory Pouchitis and Crohn‘s disease-like complications of the pouch after ileal pouch-anal anastomosis fol- lowing colectomy for ulcerative colitis. Inflamm Bowel Dis. 2018;24(2):261–268. doi: 10.1093/ibd/izx049
   PubMed Web of Science ®Google Scholar
• Chandan S, Babu M, Kumar A, et al. Safety and efficacy of biological therapy in chronic antibiotic refractory pouchitis a systematic review with meta-analysis. J Clin Gastroenterol. 2021;55(6):481–491. doi: 10.1097/MCG.0000000000001550
   PubMed Web of Science ®Google Scholar
• Kayal M, Dubinsky MC. Medical management of chronic pouch inflammation. Curr Res Pharmacol Drug Discov. 2022 Mar 3;3:100095.
   PubMedGoogle Scholar
• Travis S, Silverberg MS, Danese S, et al. Vedolizumab for the treatment of chronic pouchitis. N Engl J Med. 2023;388(13):1191–1200. doi: 10.1056/NEJMoa2208450
   PubMed Web of Science ®Google Scholar
• Harbord M, Annese V, Vavricka S, et al. The first european evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. Journal Crohn’s Colitis. 2016;10(3):239–254. doi: 10.1093/ecco-jcc/jjv213
   PubMed Web of Science ®Google Scholar
• Rogler G, Singh S, Kavanaugh A, et al. Extraintestinal manifestations of inflammatory bowel disease: Current concepts, treatment, and implications for disease management. Gastroenterology. 2021;161(4):1118–1132. doi: 10.1053/j.gastro.2021.07.042
   PubMed Web of Science ®Google Scholar
• Guillo L, D´amico F, Danese S, et al. Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: A systematic literature review. J Crohns Colitis. 2021 Jul 5;15(7):1236–1243. doi: 10.1093/ecco-jcc/jjaa260
   PubMed Web of Science ®Google Scholar
• Chateau T, Bonovas S, Le Berre C, et al. Vedolizumab treatment in extra-intestinal manifestations in inflammatory bowel disease: A systematic review. J Crohns Colitis. 2019;13(12):1569–1577. doi: 10.1093/ecco-jcc/jjz095
   PubMed Web of Science ®Google Scholar
• Galan CD, Truyens M, Peeters H, et al. The impact of vedolizumab and ustekinumab on articular extra-intestinal manifestations in inflammatory bowel disease patients: a real-life multicentric cohort study. J Crohns Colitis. 2022;16(11):1676–1686. doi: 10.1093/ecco-jcc/jjac058
   PubMed Web of Science ®Google Scholar
• Juillerat P, Grueber MM, Ruetsch R, et al. Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom? Current Res Pharmacol Drug Discov. 2022;3:100104. doi: 10.1016/j.crphar.2022.100104
   PubMedGoogle Scholar
• Laredo V, Gargallo-Puyuelo CJ, Gomollon F. How to choose the biologic therapy in a bio-naïve patient with inflammatory bowel disease. J Clin Med. 2022;11(3):829. doi: 10.3390/jcm11030829
   PubMed Web of Science ®Google Scholar
• Nguyen NH, Singh S, Sandborn WJ. Positioning Therapies in the management of Crohn’s disease. Clin Gastroenterol Hepatol. 2020;18(6):1268–1279. doi: 10.1016/j.cgh.2019.10.035
   PubMed Web of Science ®Google Scholar
• Klag T, Stange EF, Wehkamp J. Management of Crohn’s disease - are guidelines transferred to clinical practice? United Eur Gastroenterol J. 2015 Aug;3(4):371–380. doi: 10.1177/2050640615580228
   PubMed Web of Science ®Google Scholar
• Howick J, Chalmers I, Glasziou P, et al. OCEBM Levels of Evidence Working GroupOCEBM levels of evidence working group*. “The Oxford levels of evidence 2”. Oxford: Center for evidence based medicine; 2011.
   Google Scholar